Primobol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Usage

1. Review the compound's documented history and clinical data to confirm Methenolone Enanthate is appropriate for your health profile and training goals before commencing.
2. Inspect each Primobol ampoule individually: confirm the glass-fusion seal is intact, the oil solution is clear or pale yellow with no particulate matter, and the printed batch number matches the carton.
3. Warm the ampoule gently in your hand for 60 seconds if the oil has thickened in cold storage — this reduces viscosity and facilitates smooth injection, a practical tip consistent with historical clinical injection protocols for oil-based enanthate preparations.
4. Using aseptic technique, snap the ampoule at the score mark, draw the full 1 ml into a sterile syringe, and expel any air bubbles before administration.
5. Administer by deep intramuscular injection into the gluteus medius or vastus lateralis; rotate injection sites across the 10-ampoule course to minimise localised tissue build-up.
6. Record each injection date, dose, and site in a training log — consistent record-keeping allows you to correlate dosing history with bloodwork results and mirrors the pharmacovigilance traceability Balkan Pharmaceuticals builds into every numbered batch.

Warnings

Frequently asked questions

Where did Methenolone Enanthate originally come from and who developed it?

Methenolone Enanthate was developed by Schering AG in West Germany and first commercialised in the early 1960s under the Primobolan brand name. Schering scientists designed it as a clinically viable anabolic agent with a reduced androgenic burden compared to testosterone, targeting therapeutic applications in muscle-wasting and paediatric growth deficits. It remains one of the few anabolic steroids with a continuous human clinical history stretching back over six decades.

When was the injectable Methenolone Enanthate form first introduced?

The injectable depot form — Methenolone Enanthate — was introduced by Schering AG shortly after the oral acetate version, with commercial availability documented from approximately 1962–1963 in European markets. The enanthate ester was selected to provide a sustained-release profile suited to weekly or bi-weekly clinical injection schedules, reducing patient burden compared to shorter-acting alternatives available at the time.

How has Methenolone Enanthate's use evolved from its medical origins to modern performance supplementation?

Methenolone Enanthate transitioned from hospital formularies to competitive bodybuilding during the 1970s, largely because its established clinical safety data and mild androgenic profile appealed to athletes seeking anabolic support without the side-effect burden of more potent compounds. After Schering discontinued Primobolan Depot in key markets during the 1990s, GMP-certified generic manufacturers such as Balkan Pharmaceuticals re-entered the space, sustaining access to a compound whose pharmacological characteristics had remained consistent since its original design.

Why does Primobol come in 10×1 ml single-dose ampoules rather than a multi-dose vial?

Single-dose 1 ml ampoules eliminate the contamination risk created by repeatedly puncturing a multi-dose vial's rubber septum. Each Primobol ampoule is heat-sealed by glass fusion during the filling process, ensuring a sterile, hermetically closed unit. The 10-ampoule format aligns with standard injection cycle lengths and satisfies EU GMP Annex 1 aseptic-filling requirements, which prioritise container-closure integrity for parenteral oil solutions.

Is 100 mg/ml considered a low concentration for injectable Methenolone Enanthate, and does that matter?

100 mg/ml is the original clinical concentration standardised by Schering AG and remains the reference benchmark for Methenolone Enanthate injectables. While some generic manufacturers offer higher concentrations (e.g. 200 mg/ml), the 100 mg/ml formulation allows finer dose titration — particularly relevant for users managing incremental dosing adjustments — and typically exhibits lower injection-site discomfort than more concentrated oil solutions, as the active-ingredient load per unit volume is more dilute. (2) angle_used

Manufacturer

Balkan Pharmaceuticals was established in 2006 in Chișinău, Republic of Moldova, at a time when the Eastern European pharmaceutical manufacturing sector was undergoing substantial regulatory modernisation toward EU GMP harmonisation. The founding rationale centred on producing injectable and oral anabolic preparations to pharmaceutical — not grey-market — standards, a positioning decision that distinguished Balkan from many contemporaneous regional suppliers. Within its first decade, the company obtained GMP certification covering its Chișinău facility, committing to the infrastructure investments — validated clean rooms, calibrated HPLC instrumentation, documented batch-release procedures — that clinical-grade parenteral manufacturing demands. For Primobol specifically, this institutional history matters: the compound it contains, Methenolone Enanthate, has its own six-decade provenance originating with Schering AG, and Balkan's manufacturing framework is the mechanism by which that legacy molecule reaches the modern market at a confirmed 100 mg/ml specification, supported by HPLC potency verification and LAL endotoxin testing at the point of batch release.